NCT01994382 2022-04-05Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHLAlexion Pharmaceuticals, Inc.Phase 1/2 Completed260 enrolled 33 charts
NCT01445535 2021-11-03Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell LymphomasNational Institutes of Health Clinical Center (CC)Phase 1 Completed15 enrolled 18 charts
NCT00601718 2017-05-25Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell LymphomaUniversity of WashingtonPhase 1/2 Completed29 enrolled 10 charts